Michael Gelband’s Cogent Biosciences COGT Stock Holding History

Michael Gelband’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-372,175	Closed	-$14.3M	–	1639
2026 Q1	$14.3M	Buy	+372,175	New	+$13.7M	0.11%	149
2025 Q3	–	Sell	-176,276	Closed	-$1.27M	–	1604
2025 Q2	$1.27M	Buy	+176,276	New	+$977K	0.01%	893
2025 Q1	–	Sell	-67,381	Closed	-$526K	–	1538
2024 Q4	$526K	Buy	67,381 +23,404	+53%	+$233K	﹤0.01%	1141
2024 Q3	$475K	Buy	+43,977	New	+$428K	﹤0.01%	1204
2024 Q1	–	Sell	-179,415	Closed	-$1.05M	–	1552
2023 Q4	$1.05M	Buy	179,415 +158,080	+741%	+$1.21M	0.01%	801
2023 Q3	$208K	Sell	21,335 -15,505	-42%	-$184K	﹤0.01%	1513
2023 Q2	$436K	Buy	+36,840	New	+$423K	﹤0.01%	1408
2023 Q1	–	Sell	-403,625	Closed	-$4.67M	–	1803
2022 Q4	$4.67M	Buy	+403,625	New	+$5M	0.07%	371
2021 Q2	–	Sell	-217,630	Closed	-$1.91M	–	2410
2021 Q1	$1.91M	Buy	217,630 +82,780	+61%	+$797K	0.03%	586
2020 Q4	$1.51M	Buy	+134,850	New	+$1.48M	0.01%	663

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Michael Gelband's COGT Position: Q2 2026 in Review

Michael Gelband sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 372,175 shares — an estimated $14.3M sold.

Michael Gelband first reported a position in COGT in Q4 2020 and held it in 10 quarters. The position peaked at $14.3M in Q1 2026. 321 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Michael Gelband reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 372,175 Cogent Biosciences shares in Q2 2026, an estimated $14.3M.
Michael Gelband first reported a position in Cogent Biosciences in Q4 2020 and held it in 10 quarters.
Michael Gelband's Cogent Biosciences position peaked at $14.3M in Q1 2026.
321 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.